drugset / Trial / NCT06555068

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

NCT06555068

Phase 1/2 Recruiting 528 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, or HRS-1358 for advanced unresectable or metastatic breast cancer

Timeline

Start
2024-08-12
Primary completion
2027-12
Completion
2028-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fulvestrant Small molecule
Subject HRS-1358 Unknown
Subject HRS-6209 Small molecule
Subject HRS-8080 Unknown
Subject HRS-9813 Unknown
Subject Letrozole Other / unclassified

Indications